Ignite Creation Date:
2024-05-05 @ 12:04 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00237224
Status:
COMPLETED
Last Update Posted:
2009-11-19
First Post:
2005-10-09
Brief Title:
Open Label Study of Postmenopausal Women With ER and or PgR Positive Breast Cancer Treated With Letrozole
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
Open Label Study of Postmenopausal Women With ER and or PgR Positive Breast Cancer Treated With Letrozole
Status:
COMPLETED
Status Verified Date:
2009-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate safety and efficacy measured by clinical tumor response of letrozole daily dose 25 mg in postmenopausal patients with primary untreated breast cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None